1. Home
  2. Pharmaceuticals
  3. Toxoid Vaccine Market Size, Share, Growth Analysis 2032

Toxoid Vaccine Market Size, Share, Growth Analysis 2032

Toxoid Vaccine Market Size and Forecast (2025 - 2032), By Type (Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Others), By Route of Administration (Intramuscular, Subcutaneous, Others), By distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), and Geography.

Report Code: PHA00858
Report Format: PDF + PPT + Excel
Download PDF Buy Now
Report Description

Market Overview:

The global toxoid vaccine market is expected to reach a high CAGR of 5.2% over the Forecast Period 2025-2032, reaching USD XX million by 2024 and USD YY million by 2032.

North America dominates the market due to high immunisation rates and a strong healthcare infrastructure. The increasing frequency of infectious illnesses, increased government immunisation initiatives, and technological improvements in vaccine development are the primary drivers of the market expansion. However, the high costs of vaccine production and storage, as well as vaccine hesitancy in certain populations, may limit market growth to some extent.

 

Market Dynamics:

Growing Burden of Infectious Diseases Fuelling demand for toxoid vaccines

The increased global prevalence of infectious illnesses such as tetanus and diphtheria is a major driver of demand for toxoid vaccinations. The World Health Organisation estimates that 15,103 cases of tetanus were reported globally in 2019. Furthermore, the continuing COVID-19 pandemic has raised awareness of the necessity of immunisation, boosting market growth.

Increasing government initiatives for vaccination programs Driving Market Growth

Governments throughout the world are launching steps to enhance immunisation coverage through awareness campaigns, monetary support, and collaboration with international organisations. For example, in 2020, GAVI, the Vaccine Alliance, allocated approximately $1.6 billion to support immunisation programs in low- and middle-income countries. These activities are projected to increase the use of toxoid vaccinations, particularly in underdeveloped countries.

High Costs of Vaccine Development and Cold Chain Requirements Restraining Market Growth

The high capital requirements for vaccine R&D and clinical trials may impede the entry of new firms into the toxoid vaccine market. According to a 2018 vaccine study, the average cost of generating a new vaccine from preclinical to phase III trials is $200-500 million. Furthermore, the demand for cold chain storage and transportation of vaccines presents infrastructural and logistics problems, particularly in rural places, limiting market growth in some regions.

 

Segment Overview:

Tetanus Toxoid Vaccine Segment to Dominate the Market

The tetanus toxoid vaccine segment is predicted to have the highest market share over the projection period. The high incidence of tetanus, particularly in developing countries, and the inclusion of the tetanus toxoid vaccine in national immunisation regimens are significant drivers of this segment's growth. In 2020, the Indian government launched the "Intensified Mission Indradhanush 3.0" campaign, which aims to offer the tetanus toxoid vaccine to over 29 million pregnant women.

The diphtheria toxoid vaccine segment is also predicted to expand significantly in the next few years, owing to the growing frequency of diphtheria outbreaks in numerous locations. In 2019, Yemen reported over 4,000 diphtheria infections, forcing WHO and UNICEF to initiate a vaccine campaign for 2.7 million children.

The intramuscular method of administration segment accounted for the largest revenue share in 2020, owing to its extensive use for toxoid vaccine administration due to its high efficacy and safety profile. However, the subcutaneous route category is expected to develop at the quickest CAGR over the forecast period, owing to its benefits such as simplicity of administration and reduced pain.

 

Regional Outlook:

North America to Dominate the Global Toxoid Vaccine Market

North America is likely to dominate the global toxoid vaccine market during the forecast period, owing to factors such as high immunisation rates, the presence of important vaccine makers, favourable reimbursement policies, and a well-established healthcare system. The United States held the highest proportion of the North American market in 2020.

The Asia Pacific region is expected to develop at the fastest CAGR from 2024 to 2031, owing to factors such as a huge population base, improved healthcare infrastructure, more government financing for immunisation, and increased awareness of vaccine-preventable diseases. In 2021, India's Union Budget set aside Rs. 35,000 crores (US$ 4.8 billion) for the country's COVID-19 vaccination program, which includes funds for improving overall immunisation infrastructure.

 

Competitive Intelligence:

The global toxoid vaccine market is consolidated, with a few prominent companies holding a sizable market share. Leading corporations are focussing on methods such as mergers and acquisitions, partnerships, and new product launches to broaden their worldwide footprint and product portfolios.

For example, in 2020, Sanofi Pasteur paid $3.7 billion for Principia. Biopharma to boost its vaccine research and development capabilities. Key market participants include GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co., Inc., Pfizer Inc., and Emergent BioSolutions Inc., among others.

 

Analyst Opinion:

The toxoid vaccine market is expected to rise steadily in the future years, driven by rising infectious disease prevalence, increased government immunisation campaigns, and technological advances in vaccine production. To maintain long-term growth, market operators must overcome obstacles such as high development costs, cold chain constraints, and vaccination hesitancy. Strategies such as collaborative research, novel vaccination delivery technologies, and focused awareness campaigns will be critical for capitalising on growth possibilities, particularly in emerging regions.

 

Major Players:

  • GlaxoSmithKline plc

  • Sanofi Pasteur

  • Merck & Co., Inc.

  • Pfizer Inc.

  • Emergent BioSolutions Inc.

  • CSL Limited

  • Bharat Biotech

  • Biological E. Limited

  • Grifols, S.A.

  • Valneva SE

 

Key Developments:

  • In January 2022, Sanofi Pasteur announced the start of a Phase III clinical trial for their single-dose tetanus-diphtheria (Td) booster vaccine.

  • In November 2021, Bharat Biotech gained WHO prequalification for their tetanus and diphtheria (Td) vaccine, ANUTET, allowing it to supply UN agencies and GAVI.

Table of Content

1. INTRODUCTION

   1.1. Market Definitions & Study Assumptions

   1.2. Market Research Scope and Segment 

   1.3. Research Methodology

2. EXECUTIVE SUMMARY

   2.1. Market Overview & Insights

   2.2. Segment Outlook

   2.3. Region Outlook

3. COMPETITIVE INTELLIGENCE 

   3.1. Companies Financial Position

   3.2. Company Benchmarking—Key Players

   3.3. Market Share Analysis -- Key Companies

   3.4. Recent Companies Key Activities

   3.5. Pricing Analysis

   3.6. SWOT Analysis

4. COMPANY PROFILES (Key Companies List by Country) (Premium)*

5. COMPANY PROFILES

   5.1. GlaxoSmithKline plc

   5.2. Sanofi Pasteur

   5.3. Merck & Co., Inc. 

   5.4. Pfizer Inc.

   5.5. Emergent BioSolutions Inc.

   5.6. CSL Limited

   5.7. Bharat Biotech

   5.8. Biological E. Limited

   5.9. Grifols, S.A.

   5.10. Valneva SE*

6. MARKET DYNAMICS

   6.1. Market Trends

       6.1.1. Growing Burden of Infectious Diseases Fuelling demand for toxoid vaccines

       6.1.2. Technological Advancements in Vaccine Development

       6.1.3. Rising Focus on Immunisation Programs in Emerging Markets

   6.2. Market Drivers 

       6.2.1. Increasing Government Initiatives for Immunisation Programs Driving Market Growth

       6.2.2. Growing awareness about vaccine-preventable diseases

       6.2.3. Expansion of Vaccine Manufacturing Capabilities

   6.3. Market Restraints

       6.3.1. High Costs of Vaccine Development and Cold Chain Requirements Restraining Market Growth

       6.3.2. Vaccine Hesitancy and Misconceptions

   6.4. Market Opportunities

   6.5. Porter's Five Forces Analysis

       6.5.1. Threat of New Entrants

       6.5.2. Bargaining Power of Buyers/Consumers

       6.5.3. Bargaining Power of Suppliers

       6.5.4. Threat of Substitute Products

       6.5.5. Intensity of Competitive Rivalry

   6.6. Supply Chain Analysis  

   6.7. Value Chain Analysis

   6.8. Trade Analysis

   6.9. Pricing Analysis

   6.10. Regulatory Analysis 

   6.11. Patent Analysis

   6.12. SWOT Analysis

   6.13. PESTLE Analysis

7. BY TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)

   7.1. Tetanus Toxoid Vaccine

       7.1.1. Monovalent Tetanus Toxoid Vaccine

       7.1.2. Combination Tetanus Toxoid Vaccine  

   7.2. Diphtheria toxoid vaccine

       7.2.1. Monovalent Diphtheria Toxoid Vaccine

       7.2.2. Combination Diphtheria Toxoid Vaccine

   7.3. Others

       7.3.1. Pertussis Toxoid Vaccine

       7.3.2. Novel Toxoid Vaccines under Development  

8. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2025-2032)  

   8.1. Intramuscular

       8.1.1. Deltoid Muscle

       8.1.2. Vastus Lateralis Muscle

   8.2. Subcutaneous

       8.2.1. Upper Arm  

       8.2.2. Thigh

   8.3. Others 

       8.3.1. Intradermal

       8.3.2. Oral

9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)

   9.1. Hospital Pharmacies

       9.1.1. Inpatient Pharmacies

       9.1.2. Outpatient Pharmacies

   9.2. Retail Pharmacies

       9.2.1. Chain Pharmacies

       9.2.2. Independent Pharmacies  

   9.3. Online pharmacies

       9.3.1. Company-owned Online Pharmacies

       9.3.2. Third-party Online Pharmacies

10. BY REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)*

    10.1. North America

        10.1.1. United States  

        10.1.2. Canada

        10.1.3. Mexico

    10.2. South America

        10.2.1. Brazil

        10.2.2. Argentina

        10.2.3. Rest of South America

    10.3. Europe

        10.3.1. Germany

        10.3.2. United Kingdom

        10.3.3. France

        10.3.4. Italy  

        10.3.5. Spain

        10.3.6. Russia

        10.3.7. Rest of Europe

    10.4. Asia-Pacific

        10.4.1. China

        10.4.2. Japan

        10.4.3. India 

        10.4.4. Australia

        10.4.5. South Korea

        10.4.6. Rest of Asia-Pacific

    10.5. Middle-East

        10.5.1. UAE  

        10.5.2. Saudi Arabia

        10.5.3. Turkey

        10.5.4. Rest of Middle East

    10.6. Africa

        10.6.1. South Africa

        10.6.2. Egypt  

        10.6.3. Rest of Africa

 

*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (2025-2032)

Scope of the Report

By Type:

  • Tetanus Toxoid Vaccine

  • Diphtheria toxoid vaccine

  • Others

By Route of Administration:

  • Intramuscular

  • Subcutaneous

  • Others

By Distribution Channel:

  • Hospital Pharmacies

  • Retail pharmacies

  • Online pharmacies

By Region:

  • North America

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East & Africa

Frequently Asked Questions

We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.

At aurorawaveintellects.com, we believe that every industry is important to us. Our extensive team of analysts give equal focus to various industries in order to cater to our client needs, some of them being – Healthcare & Pharma, Medical, Automotive, Electric, Chemical, Manufacturing, Energy & Power, Consumer Goods etc.
Our core expertise lies in gaining deeper insights from reliable and trusted voices in the market. We always analyse market trends over the course of multiple years and examine which topics are most relevant to our clients. We pay a great deal of attention to emerging trends, niche technologies, and the latest innovations and research to bring out the best that we can offer.
We understand that every client is different and so is their requirement. While we try to gauge our clients’ needs, we are unable to cover every possible angle of a market in an off-the-shelf report. Hence, we also provide customization options to our reports to suit your needs. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com.
Our Research Reports give insights into a gamut of qualitative and quantitative topics. Every Research Report contains the following: • Market landscape • Market size • Market segmentation • Market drivers, challenges, and trends • Vendor landscape For more detail on what a specific report contains, click on report details to know more. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com
Our Research Reports are frequently updated with new data and predictions. We also have reports from previous years for specific topics. If you need help, contact us at info@aurorawaveintellects.com and we will be happy to assist you for your query.

We at aurorawaveintellects.com offer mainly 3 types of licenses:

• Single User: Research Report copy can be distributed to a single user only

• Multi User: Research Report distribution is restricted up to 5 users.

• Corporate License :Research Report can be distributed across the company.

Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:

• PDF

• Word Document

• PPT

To purchase a research report, you can browse through various categories, industries or topics and choose a particular report. Next, choose a license type and add the report to your cart. Then simply check out and complete the payment transaction and your report will be delivered to your inbox via email..

Following modes are available for making the payment:

• Online Payment (Visa Card, Master Card, Stripe)

• Razorpay

• Net Banking

• Bank Wire Transfer

At Research Reports Inc., we believe in providing the best value and offering competitive pricing to our customers to reflect that value. However, if you would still like to find out about discounts and offers, please get in touch with us at info@aurorawaveintellects.com.
Yes, you can purchase individual sections of the report. Please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.
As soon as the purchase process is over and the payment transaction is complete, you will receive the receipt via email.
The purchased Research Report is delivered to your registered email address within 48 hours of receipt of payment. If in case you did not, please check your spam folder. If you still haven’t received it, please get in touch with us at info@aurorawaveintellects.com
If you would like to receive a hard copy of the report, please get in touch with us at info@aurorawaveintellects.com with details about your purchase and we will process the same.
At aurorawaveintellects.com, we offer strong after-sales support with every purchase. Feel free to call us or email us with your queries and we will ensure they are addressed appropriately.
The Research Reports we provide are designed to cater to all market participants across the value chain. However, we do understand that every report may or may not meet the exact client requirement. For any specific change or customization in the report, please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.

Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:

• Email: info@aurorawaveintellects.com

• United Kingdom: ++91 7382742511